Does NKTR pay dividends?

Nektar Therapeutics (NKTR) does not currently pay a regular dividend.

What is NKTR's market cap?

Nektar Therapeutics (NKTR) has a market capitalization of $2.44B with a current stock price of $71.38.

Nektar Therapeutics (NKTR)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$71.38

-1.14 (-1.57%)

Market Cap: $2.44B

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

75%(30/40)

Avg Surprise

+12.11%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-2.26

Range$-3.07 - $-1.80

4 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$-0.52+77.2%

60d ago$-0.52+77.2%

30d ago$-0.52+77.2%

7d ago$-0.48+78.7%

Current$-2.26

Revenue Consensus

$10M

Range$10M - $12M

12 analysts

Period ending Dec 31, 2026

EPS Consensus$-2.69

Range$-3.85 - $-1.75

4 analysts

Revenue Consensus

$10M

Range$9M - $13M

12 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-2.69	$-3.85 - $-1.75	-	-	4	-	-
Sep 30, 2026Sep 26EST	-	$-2.26	$-3.07 - $-1.80	-	-	4	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-1.23	$-2.06	$-2.74 - $-1.72	+40.29%	Beat	4	2 0 30d	+58.3%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-1.78	$-1.48	$-1.83 - $-1.22	-20.27%	Miss	4	1 0 30d	+50.7%
Dec 31, 2025Dec 25 Reported Mar 12, 2026Reported Mar 12	$-1.29	N/A	-	+63.10%	Beat	2	No revisions (30d)	-759.9%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-1.87	$-2.79	$-3.23 - $-2.32	+32.97%	Beat	3	1 0 30d	+29.4%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-2.95	$-3.13	$-3.43 - $-2.81	+5.75%	Beat	2	0 1 30d	-5.0%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-3.61	$-2.82	$-2.84 - $-2.80	-28.01%	Miss	3	1 0 30d	-30.8%
Dec 31, 2024Dec 24 Reported Mar 12, 2025Reported Mar 12	$-0.15	$-0.13	$-0.14 - $-0.11	-15.38%	Miss	2	1 0 30d	+31.8%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-2.65	$-3.09	$-3.14 - $-3.04	+14.24%	Beat	7	No revisions (30d)	+7.0%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-2.81	$-3.01	$-3.05 - $-2.98	+6.64%	Beat	5	No revisions (30d)	+30.6%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-2.76	$-3.07	$-3.10 - $-3.05	+10.10%	Beat	3	No revisions (30d)	+26.4%
Dec 31, 2023Dec 23 Reported Mar 4, 2024Reported Mar 4	$-0.22	$-0.21	$-0.33 - $-0.15	-4.76%	Miss	5	No revisions (30d)	+31.3%
Sep 30, 2023Sep 23 Reported Nov 7, 2023Reported Nov 7	$-2.85	$-2.40	$-2.47 - $-2.35	-18.75%	Miss	7	1 0 30d	+38.7%
Jun 30, 2023Jun 23 Reported Aug 8, 2023Reported Aug 8	$-4.05	$-3.30	$-3.44 - $-3.24	-22.73%	Miss	8	No revisions (30d)	+68.2%
Mar 31, 2023Mar 23 Reported May 9, 2023Reported May 9	$-3.75	$-3.59	$-3.67 - $-3.50	-4.46%	Miss	7	No revisions (30d)	+49.0%
Dec 31, 2022Dec 22 Reported Feb 28, 2023Reported Feb 28	$-0.32	$-0.45	$-0.55 - $-0.24	+28.89%	Beat	10	1 0 30d	+59.5%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-4.65	$-6.54	$-6.75 - $-6.38	+28.90%	Beat	10	No revisions (30d)	+55.7%
Jun 30, 2022Jun 22 Reported Aug 4, 2022Reported Aug 4	$-12.75	$-15.25	$-15.47 - $-14.94	+16.39%	Beat	10	No revisions (30d)	-23.2%
Mar 31, 2022Mar 22 Reported May 5, 2022Reported May 5	$-7.35	$-10.01	$-10.22 - $-9.82	+26.57%	Beat	11	5 2 30d	+27.9%
Dec 31, 2021Dec 21 Reported Feb 28, 2022Reported Feb 28	$-0.79	$-0.81	$-0.89 - $-0.71	+2.47%	Beat	13	1 0 30d	-21.5%
Sep 30, 2021Sep 21 Reported Nov 4, 2021Reported Nov 4	$-10.50	$-12.09	$-12.17 - $-12.02	+13.15%	Beat	11	3 0 30d	-14.8%
Jun 30, 2021Jun 21 Reported Aug 5, 2021Reported Aug 5	$-10.35	$-10.98	$-11.03 - $-10.92	+5.74%	Beat	12	1 0 30d	-53.3%
Mar 31, 2021Mar 21 Reported May 6, 2021Reported May 6	$-10.20	$-10.90	$-11.02 - $-10.76	+6.42%	Beat	10	No revisions (30d)	-1824.5%
Dec 31, 2020Dec 20 Reported Feb 25, 2021Reported Feb 25	$-0.65	$-0.68	$-0.80 - $0.04	+4.41%	Beat	13	1 0 30d	+93.2%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-9.15	$-11.28	$-11.38 - $-11.05	+18.88%	Beat	13	No revisions (30d)	-8.9%
Jun 30, 2020Jun 20 Reported Aug 6, 2020Reported Aug 6	$-6.75	$-10.32	$-10.39 - $-10.23	+34.59%	Beat	14	No revisions (30d)	+28.6%
Mar 31, 2020Mar 20 Reported May 7, 2020Reported May 7	$-0.53	$-0.77	$-0.88 - $-0.43	+31.17%	Beat	14	No revisions (30d)	+94.8%
Dec 31, 2019Dec 19 Reported Feb 27, 2020Reported Feb 27	$-9.60	$-10.30	$-10.38 - $-10.15	+6.80%	Beat	13	No revisions (30d)	-1584.2%
Sep 30, 2019Sep 19 Reported Nov 6, 2019Reported Nov 6	$-8.40	$-10.83	$-10.92 - $-10.75	+22.44%	Beat	13	No revisions (30d)	+0.0%
Jun 30, 2019Jun 19 Reported Aug 8, 2019Reported Aug 8	$-9.45	$-12.00	$-12.06 - $-11.95	+21.25%	Beat	11	1 0 30d	-111.8%
Mar 31, 2019Mar 19 Reported May 8, 2019Reported May 8	$-10.20	$-11.34	$-11.48 - $-11.00	+10.05%	Beat	11	No revisions (30d)	-13.3%
Dec 31, 2018Dec 18 Reported Feb 28, 2019Reported Feb 28	$-0.57	$-0.65	$-0.80 - $0.65	+12.31%	Beat	11	No revisions (30d)	-418.2%
Sep 30, 2018Sep 18 Reported Nov 7, 2018Reported Nov 7	$-8.40	$-9.46	$-9.56 - $-9.35	+11.21%	Beat	8	No revisions (30d)	-251.4%
Jun 30, 2018Jun 18 Reported Aug 8, 2018Reported Aug 8	$79.95	$79.30	$78.40 - $79.97	+0.82%	Beat	10	No revisions (30d)	+1466.7%
Mar 31, 2018Mar 18 Reported May 10, 2018Reported May 10	$-9.00	$-8.20	$-8.99 - $-2.81	-9.76%	Miss	10	No revisions (30d)	-2042.9%
Dec 31, 2017Dec 17 Reported Mar 1, 2018Reported Mar 1	$-0.11	N/A	-	+68.57%	Beat	7	No revisions (30d)	+97.4%
Sep 30, 2017Sep 17 Reported Nov 7, 2017Reported Nov 7	$5.55	$3.36	$2.99 - $3.46	+65.18%	Beat	7	No revisions (30d)	+215.6%
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-5.85	$-5.45	$-5.51 - $-5.36	-7.34%	Miss	7	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$-0.42	$-0.42	-	+0.00%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Mar 1, 2017Reported Mar 1	$-4.20	$-4.01	-	-4.74%	Miss	-	-	-
Sep 30, 2016Sep 16 Reported Nov 3, 2016Reported Nov 3	$-4.80	$-5.40	-	+11.11%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-11.57	EV/EBITDA	-6.50x
Price/FCF	-10.08x	FCF Yield	-9.92%
Profitability
Profit Margin	-287.80%	Operating Margin	-412.20%
ROE	-35.80%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	-4.56x
Current Ratio	10.42x	Quick Ratio	10.42x
Trading Statistics
Beta	1.16	Avg Volume	570.14K
52-Week High	$109.00	52-Week Low	$27.87

Technical Indicators Dashboard

Moving Averages

SMA 10$73.91

SMA 20$74.15

SMA 50$70.94

SMA 200$64.58

EMA 10$73.46

EMA 20$73.27

EMA 50$71.70

EMA 200$63.45

MACD

Line: 0.61Signal: 1.12Hist: -0.50

ADX

ADX: 9.7+DI: 16.7-DI: 24.0

Aroon & PSAR

Aroon Up52.0

Aroon Down20.0

PSAR$76.79

Bollinger Bands

Upper Band$76.94

Lower Band$71.35

%B Position754%(Upper)

Band Width0.01

RSI (14-Day)

Neutral

45.5

Momentum Oscillators

Stoch %K36.6

Stoch %D47.2

Williams %R-80.9

ROC (10d)-1.8%

Momentum-1.29

CCI (20d)-166.8

MFI (14d)41.1

Volatility Measures

ATR (14d)$3.01(4.2%)

StdDev (20d)1.40

Hist Vol32.9%(Moderate)

Volume Flow

VWAP$71.19

OBV67.3M

AD Line41.7B

CMF (20d)0.099

Volume Metrics

Avg Vol (20d)568.1K

Vol Ratio0.7x

VWMA (20d)$74.18

Pivot Points

R3$78.14

R2$76.49

R1$74.50

Pivot Point$72.85

S1$70.87

S2$69.22

S3$67.23

Advanced Oscillators

TSI7.22

Ultimate Osc49.9

KST48.36

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$10.13M	$10.86M	$21.81M	$11.79M	$11.18M	$10.46M	$29.18M	$24.12M	$23.49M	$21.64M	$23.89M	$24.14M
Cost of Revenue	$0	$0	$0	$0	$0	$0	$7.98M	$4.43M	$9.74M	$8.53M	$7.28M	$12.43M
Gross Profit	$10.13M	$10.86M	$21.81M	$11.79M	$11.18M	$10.46M	$21.20M	$19.69M	$13.75M	$13.11M	$16.60M	$11.71M

Operating Expenses	$52.47M	$49.91M	$49.47M	$43.46M	$47.41M	$54.99M	$6.85M	$54.03M	$63.52M	$48.53M	$50.11M	$56.58M
R&D	$39.13M	$35.68M	$29.71M	$27.25M	$29.89M	$30.48M	$28.75M	$35.03M	$29.72M	$27.41M	$29.94M	$24.07M
SG&A	$12.77M	$13.44M	$11.19M	$16.07M	$17.07M	$24.35M	$17.14M	$18.96M	$20.51M	$20.15M	$17.32M	$21.15M
Operating Income	$-42,341,000	$-39,054,000	$-27,665,000	$-31,672,000	$-36,230,000	$-44,535,000	$14.35M	$-34,345,000	$-49,774,000	$-35,427,000	$-33,511,000	$-44,864,000

Interest Income	$9.35M	$4.24M	$2.78M	$2.82M	$1.97M	$2.87M	$2.94M	$3.44M	$3.90M	$4.22M	$4.62M	$5.21M
Interest Expense	$7.21M	$7.94M	$9.77M	$6.05M	$5.39M	$4.97M	$10.15M	$6.02M	$6.41M	$5.53M	$6.87M	$5.91M
Income Before Tax	$-40,301,000	$-43,090,000	$-34,702,000	$-35,021,000	$-39,395,000	$-46,369,000	$7.00M	$-37,048,000	$-52,317,000	$-36,837,000	$-42,108,000	$-45,898,000
Income Tax Expense	$2,000	$64,000	$31,000	$-33,000	$-188,000	$52,000	$-259,000	$9,000	$46,000	$-35,000	$-29,000	$-61,000

Net Income	$-40,622,000	$-44,904,000	$-36,079,000	$-35,522,000	$-41,593,000	$-50,882,000	$7.26M	$-37,057,000	$-52,363,000	$-36,802,000	$-42,079,000	$-45,837,000

EBITDA	$-45,855,000	$-40,902,000	$-29,407,000	$-33,030,000	$-36,625,000	$-45,167,000	$13.01M	$-35,536,000	$-50,935,000	$-36,982,000	$-38,206,000	$-43,504,000
EBIT	$-42,441,000	$-39,390,000	$-27,709,000	$-31,793,000	$-35,970,000	$-44,269,000	$14.21M	$-34,465,000	$-49,810,000	$-35,526,000	$-39,858,000	$-45,199,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NKTR

News

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NASDAQ:NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to contact them for more information and to assist with the investigation. The firm operates on a contingency fee basis, meaning investors incur no upfront costs.

ACCESS Newswire•Aug 25, 2026 10:44 PM8/25/26•

Bearish

Rezpegaldesleukin Improves Atopic Dermatitis in Phase 2b Trial

Nektar Therapeutics announced positive 16-week induction results from the phase 2b REZOLVE-AD trial of rezpegaldesleukin for moderate to severe atopic dermatitis, published in The Lancet. The trial met its primary endpoint, showing significant and dose-dependent reductions in Eczema Area and Severity Index (EASI) across all three dosing regimens. These findings support the continued development of rezpegaldesleukin, which selectively expands regulatory T cells to restore immune balance, in the ongoing phase 3 ZENITH AD program.

Dermatology Times•Aug 25, 2026 7:44 PM8/25/26•

Bullish

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics announced the publication of positive Phase 2b REZOLVE-AD trial results for rezpegaldesleukin in The Lancet. The study demonstrated significant improvements in moderate-to-severe atopic dermatitis patients, meeting all primary and key secondary endpoints with a favorable safety profile. These findings support the ongoing Phase 3 ZENITH AD clinical program, highlighting rezpegaldesleukin's potential as a novel T-reg modulating therapy.

Yahoo Finance•Aug 25, 2026 12:44 PM8/25/26•

Bullish

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics announced the publication of positive Phase 2b REZOLVE-AD study results for rezpegaldesleukin in moderate-to-severe atopic dermatitis in The Lancet. The study met all primary and key secondary endpoints, demonstrating significant improvements in disease severity, itch, and patient-reported outcomes with a favorable safety profile. These findings support the ongoing Phase 3 ZENITH AD clinical program, highlighting rezpegaldesleukin's potential as a novel treatment modulating regulatory T-cells to restore immune balance.

PR Newswire•Aug 25, 2026 12:12 PM8/25/26•

Bullish

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) following potential corporate wrongdoing. The firm is encouraging shareholders who purchased NKTR securities before February 26, 2025, and still hold them, to come forward. This investigation aims to restore investor capital and ensure corporate accountability on a contingency fee basis.

ACCESS Newswire•Aug 23, 2026 6:14 PM8/23/26•

Bearish

Frequently Asked Questions About NKTR

Does NKTR pay dividends?: Nektar Therapeutics (NKTR) does not currently pay a regular dividend.
What is NKTR's market cap?: Nektar Therapeutics (NKTR) has a market capitalization of $2.44B with a current stock price of $71.38.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In